Reply

Affiliations

¹ Department of Medicine II University HospitalLudwig Maximilian University Munich Munich Germany German Cancer Consortium Partner Site Munich Munich Germany Division of HepatologyDepartment of Medicine II University Hospital Würzburg Würzburg Germany Department of Radiology University HospitalLudwig Maximilian University Munich Munich Germany Department of General-, Visceral- and Transplantation-Surgery University HospitalLudwig Maximilian University Munich Munich Germany.

Comment

Najib Ben Khaled et al. Liver Transpl. 2022 May.

. 2022 May;28(5):897-898.

doi: 10.1002/lt.26410. Epub 2022 Mar 10.

¹ Department of Medicine II University HospitalLudwig Maximilian University Munich Munich Germany German Cancer Consortium Partner Site Munich Munich Germany Division of HepatologyDepartment of Medicine II University Hospital Würzburg Würzburg Germany Department of Radiology University HospitalLudwig Maximilian University Munich Munich Germany Department of General-, Visceral- and Transplantation-Surgery University HospitalLudwig Maximilian University Munich Munich Germany.

No abstract available

Comment on

Preliminary Evaluation of Atezolizumab Plus Bevacizumab as Salvage Treatment for Recurrent Hepatocellular Carcinoma After Liver Transplantation.
Yang Z, Sun J, Zhuang L, Mou H, Zheng S. Yang Z, et al. Liver Transpl. 2022 May;28(5):895-896. doi: 10.1002/lt.26416. Epub 2022 Feb 24. Liver Transpl. 2022. PMID: 35090081 No abstract available.

1. Yang Z, Sun J, Zhuang L, Mou H, Zheng S. Preliminary evaluation of atelizumab plus bevacizumab as salvage treatment for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2022;28:895–896.
1. Munker S, De Toni EN. Use of checkpoint inhibitors in liver transplant recipients. United European Gastroenterol J 2018;6:970–973.
1. d'Izarny‐Gargas T, Durrbach A, Zaidan M. Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: a systematic review. Am J Transplant 2020;20:2457–2465.
1. Qiao Z‐Y, Zhang Z‐J, Lv Z‐C, Tong H, Xi Z‐F, Wu H‐X, et al. Neoadjuvant programmed cell death 1 (PD‐1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: a cohort study and literature review. Front Immunol 2021;12(2770):653437.